Holen Sie sich die Stockscreener-App
20.37
3.64%
-0.77
Handel nachbörslich:
20.37
Schlusskurs vom Vortag:
$21.14
Offen:
$21.32
24-Stunden-Volumen:
1.08M
Relative Volume:
0.86
Marktkapitalisierung:
$1.31B
Einnahmen:
$193.35M
Nettoeinkommen (Verlust:
$-177.58M
KGV:
-8.3143
EPS:
-2.45
Netto-Cashflow:
$-172.43M
1W Leistung:
-4.90%
1M Leistung:
-4.95%
6M Leistung:
+5.54%
1J Leistung:
-10.22%
1-Tages-Spanne:
$20.15
$21.35
1-Wochen-Bereich:
$20.15
$22.15
52-Wochen-Spanne:
$16.60
$28.47
Schrodinger Inc Stock (SDGR) Company Profile
Firmenname
Schrodinger Inc
Sektor
Branche
Telefon
503-299-1150
Adresse
1540 BROADWAY, NEW YORK, NY
Vergleichen Sie SDGR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SDGR
Schrodinger Inc
|
20.37 | 1.57B | 193.35M | -177.58M | -172.43M | -2.45 |
|
VEEV
Veeva Systems Inc
|
279.32 | 45.86B | 2.86B | 780.66M | 1.20B | 4.72 |
|
TEM
Tempus Ai Inc
|
55.89 | 10.13B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
DOCS
Doximity Inc
|
62.05 | 11.55B | 550.17M | 201.35M | 232.07M | 1.00 |
|
HQY
Healthequity Inc
|
96.18 | 8.92B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
37.97 | 6.59B | 906.14M | -52.62M | 89.62M | -0.3621 |
Schrodinger Inc Stock (SDGR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-07-02 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-05 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2023-05-05 | Fortgesetzt | Piper Sandler | Overweight |
| 2022-12-19 | Eingeleitet | Goldman | Neutral |
| 2022-03-01 | Eingeleitet | Citigroup | Buy |
| 2021-11-19 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-11-11 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-10-13 | Eingeleitet | Berenberg | Buy |
| 2021-09-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-05-25 | Eingeleitet | Craig Hallum | Buy |
| 2020-11-23 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-10-12 | Hochstufung | Jefferies | Hold → Buy |
| 2020-03-02 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-03-02 | Eingeleitet | Jefferies | Hold |
| 2020-03-02 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Schrodinger Inc Aktie (SDGR) Neueste Nachrichten
What makes Schrödinger Inc. stock price move sharplyMoney Making Low Risk Plans - beatles.ru
Morgan Stanley Assumes Coverage on Schrödinger (SDGR) Stock - MSN
BMO Capital Remains a Buy on Schrodinger (SDGR) - The Globe and Mail
(SDGR) On The My Stocks Page - news.stocktradersdaily.com
Schrödinger (SDGR) Receives FDA Fast Track Designation for Cancer Drug SGR-1505 - MSN
Schrodinger stock rating assumed by Morgan Stanley at Equalweight - Investing.com India
Schrödinger Demonstrates Corporate Sustainability Progress in 2024 Report - ReportAlert
Schrödinger gets Fast Track status for SGR-1505 - MSN
Schrödinger (SDGR) Gains FDA Fast Track for MALT1 Inhibitor - GuruFocus
Schrödinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenström Macroglobulinemia | SDGR Stock News - GuruFocus
Schrödinger’s MALT1 inhibitor receives FDA fast track designation - Investing.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc.SDGR - PR Newswire
Schrodinger Announces Board Elections and Approvals - TipRanks
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger - Bluefield Daily Telegraph
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | SDGR Stock News - GuruFocus
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Where are the Opportunities in (SDGR) - news.stocktradersdaily.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, ... - Eagle-Tribune
Harbor Capital Advisors Inc. Grows Stake in Schrödinger, Inc. (NASDAQ:SDGR) - Defense World
Schrödinger slides after early-stage trial data for cancer therapy - MSN
Schrödinger: Assessing The Signal And The Noise In The Phase 1 Results - Seeking Alpha
Schrödinger (SDGR) Shares Dip After Initial Phase 1 Trial Data - GuruFocus
Schrödinger Reports Encouraging Initial Phase 1 Clinical Data fo - GuruFocus
Schrodinger Reports 22% Response Rate in Phase 1 Trial of SGR-1505 for B-Cell Cancers; Shares Fall - MarketScreener
Schrödinger stock slides on cancer trial data (SDGR:NASDAQ) - Seeking Alpha
Transcript : Schrödinger, Inc.Special Call - MarketScreener
Schrodinger (SDGR) Reports Promising Phase 1 Results of SGR-1505 | SDGR Stock News - GuruFocus
Schrödinger Reports Encouraging Initial Phase 1 Clinical Data for SGR-1505 at EHA Annual Congress - Eagle-Tribune
Day 9 of Gains Streak for Schrodinger Stock with 24% Return (vs. 38% YTD) [6/11/2025] - Trefis
Schrodinger Inc (SDGR) Trading 5.17% Higher on Jun 11 - GuruFocus
California State Teachers Retirement System Reduces Holdings in Schrödinger, Inc. (NASDAQ:SDGR) - Defense World
Schrödinger, Inc. (NASDAQ:SDGR) Receives Average Recommendation of “Buy” from Analysts - Defense World
Comparing Schrödinger (NASDAQ:SDGR) & Salarius Pharmaceuticals (NASDAQ:SLRX) - Defense World
Schrödinger's Stock in a Quantum State: Fraud Probe and Leadership Shake-Up Cloud the Outlook - AInvest
Schrodinger Inc (SDGR) Trading 4.34% Higher on Jun 6 - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Schrodinger Shows Rising Price Performance With Jump To 82 RS Rating - Investor's Business Daily
Bronstein, Gewirtz & Grossman, LLC Is Investigating Schrödinger, Inc. (SDGR) And Encourages Shareholders to Connect - ACCESS Newswire
Kalkine NASDAQ 100 Top Stocks Leading Technology Giants Driving Market Growth - Kalkine Media
24,500 Shares in Schrödinger, Inc. (NASDAQ:SDGR) Acquired by Two Sigma Advisers LP - Defense World
Bank of America Corp DE Reduces Stock Position in Schrödinger, Inc. (NASDAQ:SDGR) - Defense World
Schrodinger at Jefferies Conference: Strategic Growth and Challenges By Investing.com - Investing.com Canada
Schrodinger at Jefferies Conference: Strategic Growth and Challenges - Investing.com Australia
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Schrödinger, Inc. (SDGR) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Two Sigma Investments LP Acquires New Stake in Schrödinger, Inc. (NASDAQ:SDGR) - Defense World
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Schrödinger, Inc. (SDGR) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Top 5 AI & Digital Biotech Companies (June 2025) - Securities.io
Schrödinger, Inc. (SDGR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
ProShare Advisors LLC Has $323,000 Stock Position in Schrödinger, Inc. (NASDAQ:SDGR) - Defense World
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer - 01net
Finanzdaten der Schrodinger Inc-Aktie (SDGR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Schrodinger Inc-Aktie (SDGR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Akinsanya Karen | President of R&D, Therapeutics |
Apr 14 '25 |
Sale |
25.09 |
16,723 |
419,570 |
15,625 |
6.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):